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Background: Identification of new cancer antigens is necessary for the efficient diagnosis and immunotherapy. A
variety of tumor antigens have been identified by several methodologies. Among those antigens, cancer/testis (CT)
antigens have became promising targets.
Methods: The serological identification of antigens by the recombinant expression cloning (SEREX) methodology
has been successfully used for the identification of cancer/testis (CT) antigens. We performed the SEREX analysis of
colon cancer.
Results: We isolated a total of 60 positive cDNA clones comprising 38 different genes. They included 2 genes with
testis-specific expression profiles in the UniGene database, such as TEKT5 and a CT-like gene, A kinase anchoring
protein 3 (AKAP3). Quantitative real-time RT-PCR analysis showed that the expression of TEKT5 was restricted to the
testis in normal adult tissues. In malignant tissues, TEKT5 was aberrantly expressed in a variety of cancers, including
colon cancer. A serological survey of 101 cancer patients with different cancers by ELISA revealed antibodies to
TEKT5 in 13 patients, including colon cancer. None of the 16 healthy donor serum samples were reactive in the
same test.
Conclusion: We identified candidate new CT antigen of colon cancer, TEKT5. The findings indicate that TEKT5 is
immunogenic in humans, and suggest its potential use as diagnostic as well as an immunotherapeutic reagent for
cancer patients.
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Colon cancer is one of the major human malignancies.
Over the past decade, the overall incidence and resulting
deaths have been declining due to early diagnosis [1].
However, a majority of cases still have a poor prognosis
even with the advances in chemotherapy and molecular
targeted therapy. Recent progress in tumor immunology
based on the molecular identification of tumor antigens
may allow immunotherapy to become another promising
treatment to improve outcomes.
A variety of tumor antigens have been identified by
several methodologies. Among antigens, cancer/testis
(CT) antigens have became promising targets for diag-
nosis and immunotherapy for patients with various
tumors because of their unique expression pattern [2,3].* Correspondence: onot@md.okayama-u.ac.jp
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reproduction in any medium, provided the orThe serological identification of antigens by the recom-
binant expression cloning (SEREX) methodology has
been successfully used for the identification of CT anti-
gens. Using cDNA libraries of cancer and normal testis
tissues, SSX2 [4], SYCP-1 [5], NY-ESO-1 [6], XAGE-1
[7], and CCDC62-2 [8] have been identified.
In this study, we performed SEREX analysis of colon
cancer, and isolated a novel CT antigen, Tektin5 (TEKT5),
in addition to a previously defined CT-like antigen, A kin-
ase anchoring protein 3 (AKAP3). Tektins (TEKTs) are
composed of a family of filament-forming proteins in the
male germ cell-lineage in centrioles and basal bodies and
within ciliary and flagellar doublet microtubules [9]. In
mammals, five Tektin proteins (TEKT1 – 5) have been
identified [10]. We isolated human TEKT5, and showed
that it has the characteristics of a CT antigen and that it
elicits a strong immune response in a subset of patients
with cancer, including colon cancer.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Ethics statement
Patient samples were collected in accordance with the
Declaration of Helsinki and approved by the Ethics Com-
mittee of Okayama University Graduate School of Medi-
cine, Dentistry, and Pharmaceutical Sciences (No. 842).
Tissues and sera
Tumor specimens and sera were obtained from patients at
Okayama University Hospital. Written informed consent
was obtained from all patients and healthy donors involved
in our study in accordance with the university guidelines.
Preparation of the cDNA library
mRNA was purified from the colon cancer tissue C164
using a Quick Prep mRNA Purification Kit (Amersham
Pharmacia, Piscataway, NJ, USA). mRNA was also purified
from normal testicular total RNA. Then, a cDNA expres-
sion library was prepared in a γZAP Express vector using
a cDNA library kit (Stratagene, La Jolla, CA, USA).
Immunoscreening of cDNA libraries
A cDNA expression library of C164 colon cancer tissues
was screened with autologous patient sera. A testicular
cDNA expression library was screened with 2 different
colon cancer patient sera. The screening procedure was
described previously [11]. In brief, serum samples that
had been diluted 1:10 were preabsorbed with lysate from
Eschericia coli Y1090/Y1089 and coupled to Sepharose
4B (BioDynamics Lab Inc., Tokyo, Japan). Recombinant
phages (approximately 4,000 pfu) on agar in a plastic
dish (140-mm diameter) were amplified for 8 hr and
then transferred to 135-mm diameter nitrocellulose
membranes (Schleicher & Schuell, Dassel, Germany) for
15 hr at 37°C. The membranes were then blocked with
5% non-fat milk and pre-screened by incubation with
peroxidase-conjugated Fc fragment-specific goat anti-
human IgG (Jackson ImmunoResearch, West Grove, PA,
USA) (1:2,000 dilution) for 1 hr at room temperature.
Color was developed using 3, 3'-diaminnobenzidine
(Sigma, St. Louis, MO, USA), and IgG-encoding clones
were marked so that they could be excluded from subse-
quent examinations. The membranes were then incu-
bated overnight at room temperature with the
preabsorbed serum diluted to 1:200. The membranes
were incubated with peroxidase-conjugated Fc fragment-
specific goat anti-human IgG (Jackson ImmunoRe-
search) (1:2,000 dilution) for 1 hr at room temperature,
and then the color was developed. Positive clones were
collected and subcloned to monoclonality by 2nd and
3rd screenings using 82- and 47-mm diameter mem-
branes, respectively. A randomly chosen negative clone
was included in each assay as a negative control.Sequence analysis of reacted clones
The clones that reacted positively were subcloned to
monoclonality, purified, and excised in vivo to pBK-
CMV plasmid forms (Stratagene). The plasmid DNA
was prepared using the Quantum Prep Plasmid Mini-
prep Kit (Bio-Rad, Hercules, CA, USA). The nucleotide
sequences of the cDNA inserts were determined using
an ABI 3130x1 Genetic Analyzer (Applied Biosystems,
Foster City, CA, USA), and sequence alignment was per-
formed with BLAST software and sequences in the Gen-
Bank database.
Total RNA isolation and cDNA synthesis
Total RNA was isolated from the tumor tissues using an
RNeasy Mini Kit (Qiagen, Hilden, Germany). Total RNA
from normal testis tissues was obtained commercially
(BD Bioscience Clontech, Palo Alto, CA, USA). The
RNA (2 μg) was reverse-transcribed into single-strand
cDNA using Moloney murine leukemia virus reverse
transcriptase (Ready-To-Go You-Prime First-Strand
Beads, GE Healthcare, Buckinghamshire, UK) and oligo
(dT)15 as a primer. The cDNA samples were tested for
integrity by the amplification of G3PDH in a 30-cycle
reaction.
Quantitative real-time RT-PCR
Two-step real-time RT-PCR was performed using a Ste-
pOne Real-Time PCR System (Applied Biosystems).
cDNA was synthesized using a High-capacity cDNA Re-
verse Transcription kit (Applied Biosystems). TaqMan
Gene Expression Assays (Applied Biosystems) were used
to measure the mRNA levels of TEKT5 (Assay ID:
Hs01025979_m1). mRNA levels were expressed as n-fold
differences relative to G3PDH (internal standard) and the
levels in normal testis (calibrator). PCR was performed
using TaqMan PCR Master Mix (Applied Biosystems),
and the thermal cycling conditions comprised an initial
denaturation at 95°C for 10 min, then 40 cycles at 95°C
for 15 sec, and 60°C for 1 min. The parameter Ct was
defined as the threshold cycle number at which the fluor-
escence generated by cleavage of the probe passed above
the baseline. The TEKT5 target message was quantified
by measuring the Ct value, and transcripts of G3PDH
were quantified as an endogenous RNA control using
TaqMan human G3PDH control regents (Applied
Biosystems).
Gene expression microarrays
Gene expression was examined using Agilent Human
1A oligomicroarrays containing 60-mer DNA probes in
a 22K format (Agilent Technologies). Of 19,061 spots,
18,086 are non-controls, and there are 17,086 unique
transcript sequences from 15,989 unique human genes.
Five hundred ng of total RNA from 3 colon cancer
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the reference samples were used to synthesize labeled
cRNA (Low RNA Input Linear Amp Kit, Agilent Tech-
nologies) in the presence of cyanine 3-dCTP and cyanine
5-dCTP (Perkin-Elmer Life Sciences, Boston, MA), re-
spectively. Differentially labeled test and reference sam-
ples were mixed with Agilent control targets before
being hybridized onto the oligomicroarrays for 17 hr at
37°C in a rotating oven. The fluorescence intensities of
the targets were detected using a laser confocal scanner
(Agilent Technologies), and the resulting images were
processed using the Feature Extraction Software, version
8.4 (Agilent Technologies).
Recombinant TEKT5 protein
TEKT5 was expressed in E. coli BL21 using the GST-
containing vector pGEX-6P-1 (Amersham Biosciences).
cDNA amplification primers Eco-KT-s2 (forward: 50-
GGCGAATTCGAGTTTGGGACTACTCAG-30) and Sal-Table 1 SEREX-defined genes identified by autologous screen
Antigen No. of clones Identity/similarities
OY-CO-1 1 Lectin, galactoside-binding, soluble,
3 binding protein (LGALS3BP)
OY-CO-2 1 Rho GTPase-activating protein
18(ARHGAP18)
OY-CO-3 10 Dihydrolipoamide dehydrogenase (DLD)
OY-CO-4 1 Adenomatous polyposis coli (APC),
transcript variant 3
OY-CO-5 1 MRE11 meiotic recombination 11 homolog
transcript variant 1
OY-CO-6 1 Heat shock protein 90 kDa beta (Grp94), me
OY-CO-7 1 Transcription elongation factor B (SII), polyp
2 (18 kDa, elongin B) (TCEB2), transcript vari
OY-CO-8 1 Wilms tumor 1-associated protein (WTAP), t
OY-CO-9 1 Ribosomal protein L35a (RPL35A)
OY-CO-10 1 Polyglutamine-binding protein 1 (PQBP1), tr
OY-CO-11 2 PRP38 pre-mRNA processing factor 38 (yeas
containing B (PRPF38B), transcript variant 1
OY-CO-12 2 Coatomer protein complex, subunit alpha (C
OY-CO-13 1 Keratin 18 (KRT18), transcript variant 1
OY-CO-14 1 No strong homology, retrotransposon MSTP
OY-CO-15 1 Ribosomal protein L13 (RPL13), transcript va
OY-CO-16 1 Partial mRNA for KLEIP (kelch-like ECT2 inter
OY-CO-17 2 BTB (POZ) domain containing 2 (BTBD2)
OY-CO-18 1 Nuclear receptor interacting protein 1 (NRIP
OY-CO-19 1 Ribosomal protein L8 (RPL8), transcript varia
OY-CO-20 2 Glutamine-fructose-6-phosphate transamina
OY-CO-21 1 WD repeat, sterile alpha motif and U-box do
containing 1 (WDSUB1), transcript variant 3
1Gene expressions in 3 colon cancer tissues were compared with normal colon tissuKT-as2 (reverse: 50-ATTGTCGACGGTGTGGCCCAC
CAGGCGCGG-30) were designed to encompass the entire
coding sequence of the gene corresponding to amino acid
positions 1–486. The isolated GST fusion protein was
purified on a gel filtration column (Hiload 16/60 Superdex
200 pg, GE Healthcare).
ELISA
Recombinant TEKT5 protein (1 μg/ml) in 0.05 M car-
bonate buffer (pH 9.6) was absorbed onto 96-well plates
(Nunc) at 4°C overnight. GST protein was used as a
negative control. Plates were washed with PBS/Tween
and blocked with 5% FCS/PBS at room temperature for
1 hr. After washing, serum dilutions (100 μl) in 5% FCS/
PBS were added and incubated at room temperature for
2 hr. Plates were washed and incubated with secondary
antibody (peroxidase-conjugated Fc fragment-specific
goat anti-human IgG, Jackson ImmunoReserach) at a
1/5,000 dilution for 1 hr at room temperature. Plates wereing of C-164 cDNA library
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es by cDNA microarray analysis.
Table 2 SEREX-defined genes identified by screening of a testicular cDNA library with C-164 serum
Antigen No. of clones Identity/similarities DNA microarray (fold change) 1
C-164 C-1 C-29
OY-CO-22 1 Ribosomal protein L29 (RPL29) 1.28 0.88 1.58
OY-CO-23 1 Sperm-associated antigen (SPAG7) 1.41 0.51 0.52
OY-CO-24 1 Similar to Laminin receptor 1 (LOC388524) 1.10 1.96 1.93
OY-CO-25 1 Microfibrillar-associated protein (MFAP1) 1.30 1.51 1.35
OY-CO-26 1 Glycine cleavage system protein H (aminomethyl carrier) (GCSH),
nuclear gene encoding mitochondrial protein, transcript variant 1
2.48 2.47 0.79
OY-CO-3 2 Dihydrolipoamide dehydrogenase DLD 1.27 0.55 0.30
OY-CO-12 1 Coatomer protein complex, subunit alpha (COPA), transcript variant 2 1.26 0.73 0.75
OY-CO-17 1 BTB (POZ) domain containing 2 (BTBD2) 0.79 0.84 0.83
OY-CO-20 1 Glutamine-fructose-6-phosphate transaminase 1 (GFPT1) 2.92 1.00 0.59
OY-CO-21 1 WD repeat, sterile alpha motif and U-box domain containing 1 (WDSUB1),
transcript variant 3
1.69 1.19 0.76
1Gene expressions in 3 colon cancer tissues were compared with normal colon tissues by cDNA microarray analysis.
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phenylenediamine dihydrochloride) for 20 min at room
temperature. After the addition of 6 M H2SO4 (50 μl), the
absorbance was determined with a microplate reader
(BioRad). A positive reaction was defined as an optical
density (OD) value for 1: 400 diluted serum that exceeded
the mean OD value of sera from healthy donors by three
standard deviations.
Results
Identification of colon cancer antigens by SEREX
A cDNA expression library of 1.5 x 106 clones was pre-
pared from C164 colon cancer tissue. Immunoscreening
2.6 x 105 clones with autologous serum yielded a total of
38 positive clones. The nucleotide sequences of the
cDNA inserts identified 21 different genes, which wereTable 3 SEREX-defined genes identified by screening of a tes
Antigen No. of clones Identity/similarities
OY-CO-27 2 Chromosome 5 open reading frame 45 (C5or
OY-CO-28 2 Palladin, cytoskeletal associated protein (PALL
OY-CO-29 2 Heat shock 70 kDa protein 1A (HSPA1A)
OY-CO-30 1 Peroxisomal D3, D2-enoyl-CoA isomerase (PE
OY-CO-31 1 Phosphatidylinositol-5-phosphate-4-kinase, ty
OY-CO-32 1 Prostaglandin D2 synthase 21 kDa (brain) (PT
OY-CO-33 1 No strong homology-sequence from clone R
OY-CO-34 1 Tektin 5 (TEKT5)
OY-CO-35 1 A kinase anchor protein 3 (AKAP3)
OY-CO-36 1 Similar to hypothetical protein MGC:37569
OY-CO-37 1 Polycystic kidney disease 1 (autosomal domin
OY-CO-38 1 Coiled-coil domain containing 19 (CCDC19)
1 Gene expressions in 3 colon cancer tissues were compared with normal colon tissdesignated as OY-CO-1 to OY-CO-21 (Table 1). OY-CO-3,
represented by 10 clones, was identical to Homo sapiens
Dihydrolipoamide dehydrogenase (DLD).
A cDNA expression library of 1 x 106 clones was pre-
pared from normal testicular total RNA. Immunoscreen-
ing of 1.6 x 105 clones with C164 colon cancer patient
serum yielded a total of 11 positive clones. The nucleo-
tide sequences of the cDNA inserts identified 10 differ-
ent genes. Among them, 5 genes: DLD, COPA, BTBD2,
GFPT1, and WDSUB1, were also isolated in the autolo-
gous serum screening (Table 2).
A total of 1.6 x 105 clones from the testicular cDNA li-
brary were also immunoscreened with another colon cancer
patient serum. As shown in Table 3, 15 positive clones
representing 12 genes were isolated, including 2 genes with
testis-specific expression profiles in the Unigene database.ticular cDNA library with C-18 serum
DNA microarray (fold change) 1
C-164 C-1 C-29
f45), transcript variant 1 0.72 0.92 1.88
D), transcript variant 2 0.04 0.30 1.89
2.79 1.72 0.61
CI), transcript variant 1 0.11 1.65 0.60
pe II, alpha (PIP4K2A) 1.82 0.14 2.21
GDS) 0.19 0.56 0.19




ant) (PKD1), transcript variant 1 0.42 0.73 0.76
3.23 1.67 0.74
ues by cDNA microarray analysis.
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http://www.biomedcentral.com/1471-2407/12/520OY-CO-35, represented by a single clone, was identical to a
CT-like gene, AKAP3. OY-CO-36, represented by a single
clone, was identical to Tektin 5 (TEKT5).
Gene expression profiles of SEREX-defined genes
Gene expression analysis was performed on 3 colon can-
cer specimens including C164 used in SEREX, with a
cDNA microarray. Of 38 SEREX-defined genes, ten genes
showed higher expression levels in all 3 colon cancer spe-
cimens compared with normal colon tissue. MRE11A and
PRPF38B showed more than 2.5-fold expression in all



























































































Figure 1 Quantitative real-time RT-PCR analysis of TEKT5 and NY-ESO
indicated. (B) Expression in colon cancer, gastric cancer, head & neck canceregulated in 2 colon cancer specimens (3.55- and 7.96-fold).
AKAP3 expression was also up-regulated in 2 colon cancer
specimens.
TEKT5 mRNA expression in normal and malignant tissues
To investigate TEKT5 mRNA expression in normal tis-
sues, we performed quantitative real-time RT-PCR ana-
lysis using a TEKT5-specific TaqMan probe. For
comparison, a prototype CT antigen, NY-ESO-1 (TaqMan
Gene Expression Assays: Hs00265824_m1) was also ana-
lyzed. As shown in Figure 1A, markedly lower levels of















































-1. (A) Expression in normal adult tissues. Expression relative to testis is
r, liver cancer, lung cancer, and prostate cancer.
Table 4 Antibody response to the recombinant TEKT5







Head & Neck cancer 3/19
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http://www.biomedcentral.com/1471-2407/12/520nongametogenetic tissues compared to normal testis, as in
the case of NY-ESO-1. In malignant tissues, TEKT5
mRNA expression was detected in 5 of 10 colon cancers,
4 of 10 gastric cancers, 6 of 10 liver cancers, 1 of 10 lung
cancers, and 1 of 9 prostate cancers at >1% of the testicu-
lar expression level. Furthermore, one colon cancer
showed an expression level equivalent to the testis
(Figure 1B). NY-ESO-1 mRNA expression in the same set
of cancer specimens was also indicated in Figure 1B.
Immunogenicity of TEKT5 in cancer patients
We then investigated the immunogenicity of TEKT5. Sera
from 101 cancer patients and 16 healthy donors were
tested for IgG antibody by ELISA using recombinant
TEKT5 protein. As shown in Table 4, 4/44 sera from
colon cancer patients, 6/15 sera from liver cancer patients,
and 3/19 sera from head & neck cancer patients were re-
active against TEKT5. No TEKT5 antibody was detected
in the sera from 23 lung cancer patients. None of the 16
healthy donor serum samples were reactive in the same
test. Figure 2 illustrates titration curves with sera from
selected cancer patients and healthy donors.
Discussion
In our study, we performed the serologic search for colon
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Figure 2 ELISA reactivity of sera from cancer patients and healthy do
a serum from single patient.total of 60 positive cDNA clones consisting of 38 different
genes, designated OY-CO-1 to OY-CO-38. There were 2
genes with testis-specific expression in the UniGene data-
base and literature, such as AKAP3 and TEKT5.
AKAPs are a group of structurally diverse proteins that
bind to the regulatory subunit of PKA [12]. They are
signaling scaffolds that contribute to various aspects of
cAMP signaling [13]. It has also been demonstrated that
AKAP-mediated PKA activation inhibited cell growth
in the muscle and T lymphocytes. AKAP3 is a testis-
specific protein expressed exclusively in round
spermatides [14]. Previously, we showed that AKAP3
was a CT-like antigen, and that high AKAP3 mRNA ex-
pression was observed in ovarian cancer and the expres-
sion was correlated with the histological grade and
clinical stage of the tumor. We showed that AKAP3
mRNA expression was an independent and favorable
prognostic factor in patients with poorly differentiated
ovarian cancer [15].
TEKTs are composed of a family of filament-forming
proteins in the male germ cell-lineage in centrioles and
basal bodies and within ciliary and flagellar doublet
microtubules [9]. They were originally isolated from sea
urchin sperm [16]. Five types of mammalian Tektin have
been identified in various animals, including the mouse
[17,18], rat [19,20], and human [21,22]. TEKT5 was first
identified in the rat [19]. It is present in sperm flagella
and plays an important role in flagella formation during
spermiogenesis as well as being implicated in sperm mo-
tility. The human TEKT5 gene consists of 7 exons and is
located on chromosome 16p13.13. The deduced amino
acid sequence of human TEKT5 showed a high degree
of identity with the ortholog of the mouse (83%) and rat
(83%), respectively. Among 5 human TEKTs, the amino
acid sequence is significantly different except in the sig-
nature nonapeptide sequence region (Figure 3). Quanti-





,600        6,400 400         1,600        6,400
cer Healthy donor
 dilution
nors against TEKT5 protein. Each line represents a titration curve of
Figure 3 Sequence alignment of tektin proteins. Dot indicates the identical amino acid residues in TEKT1 to 4 with TEKT5. An asterisk
indicates fully conserved residues. The tektin signature sequence (RPNVELCRD) is boxed. Relative identities of TEKT5 to other TEKTs are 24 to 50%
(shown in parenthesis).
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http://www.biomedcentral.com/1471-2407/12/520expression of TEKT5 mRNA was restricted to the testis
in normal adult tissues. However, it was detected in sev-
eral types of cancer, including colon, gastric, liver, lung,
and prostate cancer. By cDNA microarray analysis,
TEKT5 showed higher expression levels in 2 of 3 colon
cancer tissues compared with normal tissue. It was also
up-regulated more than 3-fold in 50% of the lung can-
cers examined (data not shown). Thus, TEKT5 has a
classical feature of a CT antigen. In our survey of 101
cancer patients with several types of cancer, 13 patients
produced antibody to TEKT5 protein. No reactivity was
observed in sera from healthy donors. In terms of the
antibody frequency, TEKT5 appears to have a immuno-
genic potential as a CT antigen.
Among CT antigens, NY-ESO-1, a SEREX-defined CT
antigen, was shown to induce a frequent antibody
response in cancer patients [23,24], and strong CD4 and
CD8 T-cell responses against NY-ESO-1 were also eli-
cited [25,26]. Taken together, the findings suggest that
serologically defined TEKT5 provides a molecular basis
for diagnostic and immunotherapeutic targets in cancer
patients. Thus, the CD4 and CD8 T-cell responses
against TEKT5 will be further investigated.
Conclusions
We identified candidate new CT antigen of colon cancer,
TEKT5. The findings indicate that TEKT5 is immunogenic
in humans, and suggest its potential use as diagnostic as
well as a immunotherapeutic reagent for cancer patients.
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